[Ga]Ga-NY104 PET/CT 对识别肾透明细胞癌的诊断效能。
Diagnostic efficacy of [Ga]Ga-NY104 PET/CT to identify clear cell renal cell carcinoma.
机构信息
Department of Nuclear Medicine, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 1 Shuaifuyuan, Dongcheng District, Beijing, 100730, China.
Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 1 Shuaifuyuan, Dongcheng District, Beijing, 100730, China.
出版信息
Eur J Nucl Med Mol Imaging. 2024 Nov;51(13):4127-4133. doi: 10.1007/s00259-024-06801-y. Epub 2024 Jun 25.
PURPOSE
Most clear cell renal cell carcinoma (ccRCC) overexpresses carbonic anhydrase IX (CAIX). [Ga]Ga-NY104 is a small-molecule PET agent selectively targeting CAIX. This study aims to assess the efficacy of [Ga]Ga-NY104 PET/CT to identify ccRCC.
MATERIALS AND METHODS
Participants were prospectively recruited in the study (ClinicalTrials.gov: NCT05902377). They were further divided into two groups: group 1, patients with primary renal mass who were scheduled for surgery, group 2, patients with suspected/confirmed metastatic ccRCC. All patients underwent [Ga]Ga-NY104 PET/CT.
RESULTS
A total of 47 patients (mean age, 58.8 years ± 13.5, 34 men) were recruited, including 20 patients in group 1 and 27 patients in group 2. The patient-level sensitivity, specificity, and accuracy of [Ga]Ga-NY104 PET scan was 62%, 33%, 58% for group 1 and 95%, 100%, 96% for group 2. [Ga]Ga-NY104 PET identified additional 26 disease regions in 67% (14/21) of patients that were previously unknown. The tumor uptake was correlated with immunohistochemical staining results.
CONCLUSIONS
PET/CT has a high diagnostic efficacy for patients with metastatic ccRCC, while it might be of limited value in the diagnosis of primary ccRCC.
目的
大多数透明细胞肾细胞癌 (ccRCC) 过度表达碳酸酐酶 IX (CAIX)。[Ga]Ga-NY104 是一种小分子 PET 剂，可特异性靶向 CAIX。本研究旨在评估 [Ga]Ga-NY104 PET/CT 识别 ccRCC 的功效。
材料和方法
参与者前瞻性地被纳入研究（ClinicalTrials.gov：NCT05902377）。他们进一步分为两组：组 1，计划接受手术的原发性肾肿瘤患者；组 2，疑似/确诊转移性 ccRCC 患者。所有患者均接受 [Ga]Ga-NY104 PET/CT 检查。
结果
共招募了 47 名患者（平均年龄 58.8±13.5 岁，34 名男性），包括组 1 的 20 名患者和组 2 的 27 名患者。[Ga]Ga-NY104 PET 扫描的患者水平敏感性、特异性和准确性分别为组 1 的 62%、33%和 58%，组 2 的 95%、100%和 96%。[Ga]Ga-NY104 PET 在 67%（14/21）先前未知的患者中识别出了另外 26 个疾病区域。肿瘤摄取与免疫组织化学染色结果相关。
结论
PET/CT 对转移性 ccRCC 患者具有较高的诊断效能，而对原发性 ccRCC 的诊断价值可能有限。
Zotero 插件